Joy Nashay Edison Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4715 Leeds Ave # L2, Arbutus, MD 21227 Phone: 443-455-0519 |
News Archive
Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.
Too many stroke patients in Canada are not getting the rehabilitation they need to return to a healthy, active life, according to a new study which will be presented at the Canadian Stroke Congress in Vancouver tomorrow.
The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions.
› Verified 9 days ago